HK Stock Market Move | LUYE PHARMA(02186) rose by nearly 3%, and five new products including Mimiexin have been included in the National Medical Insurance Drug List or the Commercial Insurance Innovative Drug List.

LUYE PHARMA (02186) rose nearly 3%, as of the time of writing, it rose 2.66% to HK$3.09, with a transaction amount of HK$8.3751 million. On the news front, on December 7th, LUYE PHARMA announced that five new products from the group had been successfully included in the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalogue (2025)" (National Medical Insurance Drug Catalogue) or the "Commercial Health Insurance Innovative Drug Catalogue (2025)" (Commercial Health Insurance Innovative Drug Catalogue). The five new products include: MimiXin (hydroxyprogesterone naloxone sustained-release tablets), Ruibailai (palmitate paliperidone injection ()) included in the National Medical Insurance Drug Catalogue for the first time; Zan Bijia (injection of lubitide) successfully selected for the Commercial Health Insurance Innovative Drug Catalogue; Baituowei (injection of goserelin microspheres), Ruiketuo (injection of risperidone microspheres ()) smoothly renewed, continuing to be included in the National Medical Insurance Drug Catalogue.